Status:
COMPLETED
Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer
Lead Sponsor:
University Health Network, Toronto
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
NSCLC is the leading cause of cancer mortality in North America, accounting for nearly 30% of all cancer deaths. The standard treatment for patients with early-stage non-small-cell lung cancer (NSCLC)...
Eligibility Criteria
Inclusion
- Must have been treated at University of Health Network with SBRT for an early-stage NSCLC (T1N0M0; T2N0M0; or T3N0M0 chest wall primary tumours only).
- On follow-up thoracic CT scans, patients must have changes in the previously targeted lung parenchyma that fit into one of the following three patterns: - Changes that on CT and clinical grounds are felt to be related to fibrosis
- Changes that on CT and clinical grounds are suspicious for recurrence
- Equivocal changes (uncertain whether the changes represent fibrosis or recurrence)
- Must be greater than 18 years in age
- Must be able to attend regular follow-up including radiologic investigations and clinical visits
- Written informed consent
Exclusion
- Standard contraindications to MRI study (e.g. ferromagnetic prosthesis, pacemaker/implanted defibrillator, metallic implant in eye, severe claustrophobia, etc…)
- Contraindications to Gadolinium contrast-agent. May include a history of allergic reaction to following previous administration of gadolinium or poor renal function (calculated creatinine clearance \< 30 mL/min).
- Patients with surgical resection of the treated portion of lung following their SBRT, although surgical resection of other parts of the lung is allowed.
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 29 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01480973
Start Date
June 1 2011
End Date
May 29 2020
Last Update
October 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital, University Health Network
Toronto, Ontario, Canada, M5G 2M9